AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9493805 — intervention group
Group type: EXPERIMENTAL
Intervention: MEDI‐493 (palivizumab) 15 mg/kg
Number of subjects: 0
Study 9493805 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 0
Study 7520676 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (12 micrograms/kg of body weight per day)
Number of subjects: 218
Study 7520676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 2528257 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% azelaic acid cream
Number of subjects: 381
Study 2528257 — intervention group
Group type: COMPARATOR
Intervention: 0.05% tretinoin cream
Number of subjects: 381
Study 2528257 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 381
Study 60566 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (10 mg thrice daily)
Number of subjects: 20
Study 60566 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (50 mg/day)
Number of subjects: 20
Study 60566 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol plus Hydrochlorothiazide
Number of subjects: 20
Study 60566 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no treatment)
Number of subjects: 20
Study 31749051 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide (FAc) implant
Number of subjects: 49
Study 31749051 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 49
Study 31422789 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral angioplasty/stenting plus best medical treatment (BMT)
Number of subjects: 182
Study 31422789 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone
Number of subjects: 182
Study 26644166 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics during chemotherapy (n=30)
Number of subjects: 61
Study 26644166 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=31)
Number of subjects: 61
Study 25733548 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT)
Number of subjects: 70
Study 25733548 — intervention group
Group type: COMPARATOR
Intervention: Standard care hydrocolloid dressing
Number of subjects: 70
Study 23800627 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein formula (HP: 2.05 and 3.2 g/100 mL)
Number of subjects: 1090
Study 23800627 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower protein formula (LP: 1.25 and 1.6 g/100 mL)
Number of subjects: 1090
Study 23800627 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants (BF)
Number of subjects: 1090
Study 21856515 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally sensitive mass media intervention delivered via television and radio for more than 3 years.
Number of subjects: 1346
Study 21856515 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonmedia cities: Providence, RI; Columbia, SC).
Number of subjects: 1346
Study 19875318 — intervention group
Group type: EXPERIMENTAL
Intervention: PLGA-beta-TCP composite
Number of subjects: 30
Study 19875318 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic gauze
Number of subjects: 30
Study 19875318 — intervention group
Group type: COMPARATOR
Intervention: Buccal flap technique
Number of subjects: 30
Study 16715577 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 481
Study 16715577 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 481
Study 14687137 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based colonoscopy simulation (CBCS) training for 6 hours
Number of subjects: 8
Study 14687137 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditionally trained fellows)
Number of subjects: 8
Study 11246738 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions in phase 3 trials for urinary bladder cancer therapy
Number of subjects: 1000
Study 9223197 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 15 mg
Number of subjects: 12
Study 9223197 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 15 mg
Number of subjects: 12
Study 9223197 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 100 mg
Number of subjects: 12
Study 9223197 — intervention group
Group type: COMPARATOR
Intervention: Control (CPT before anesthesia)
Number of subjects: 12
Study 9223197 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT after spinal anesthesia
Number of subjects: 12
Study 7954529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural OK-432 injection
Number of subjects: 93
Study 7954529 — intervention group
Group type: COMPARATOR
Intervention: Control (no intrapleural OK-432 injection)
Number of subjects: 93
Study 2880885 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 9
Study 2880885 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 9
Study 2880885 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg
Number of subjects: 9
Study 2880885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31943168 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Number of subjects: 42
Study 31943168 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (subgroup analysis)
Number of subjects: 42
Study 29452584 — intervention group
Group type: EXPERIMENTAL
Intervention: P1000/Ca500 (1000 mg/d phosphorus and 500 mg/d calcium)
Number of subjects: 62
Study 29452584 — intervention group
Group type: EXPERIMENTAL
Intervention: P1000/Ca1000 (1000 mg/d phosphorus and 1000 mg/d calcium)
Number of subjects: 62
Study 29452584 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sherbet powder)
Number of subjects: 62
Study 27151156 — intervention group
Group type: EXPERIMENTAL
Intervention: VERSE therapy - a prescribed and structured aphasia therapy program, 20 additional sessions (45-60 min, provided daily) before day 50 post stroke.
Number of subjects: 246
Study 27151156 — intervention group
Group type: EXPERIMENTAL
Intervention: UC-plus usual ward-based therapy, 20 additional sessions (45-60 min, provided daily) before day 50 post stroke.
Number of subjects: 246
Study 27151156 — intervention group
Group type: COMPARATOR
Intervention: UC-no additional therapy.
Number of subjects: 246
Study 27151156 — intervention group
Group type: EXPERIMENTAL
Intervention: Discourse measures, Stroke and Aphasia Quality of Life Scale-39, and Aphasia Depression Rating Scale.
Number of subjects: 246
Study 27151156 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation of incremental cost-effectiveness ratios.
Number of subjects: 246
Study 26905548 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (100 microgram/kg IV)
Number of subjects: 90
Study 26905548 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (40 microgram/kg IV)
Number of subjects: 90
Study 23532888 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg b.i.d.) plus modified FOLFOX6 (mFOLFOX6)
Number of subjects: 198
Study 23532888 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus modified FOLFOX6 (mFOLFOX6)
Number of subjects: 198
Study 23532888 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus mFOLFOX6
Number of subjects: 198
Study 23532888 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus mFOLFOX6
Number of subjects: 198
Study 20648201 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse width programming (50-1000 microseconds)
Number of subjects: 19
Study 18826858 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet activation parameters (CD62P, CD63, PAC-1, CD42b, CD41)
Number of subjects: 93
Study 17121038 — intervention group
Group type: EXPERIMENTAL
Intervention: Xinshuai Mistura (XM)
Number of subjects: 59
Study 17121038 — intervention group
Group type: COMPARATOR
Intervention: Wuling Pulvis (WP)
Number of subjects: 59
Study 12813383 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte depletion group (n=40)
Number of subjects: 80
Study 12813383 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 80
Study 10867764 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularization (TMR) using holmium:yttrium‐aluminium‐garnet (YAG) and carbon dioxide lasers
Number of subjects: 0
Study 10867764 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularization (TMR) as an adjunct to coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 10867764 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 0
Study 8795804 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg p.o. taken at 20.00 hours for 1 week
Number of subjects: 15
Study 8795804 — intervention group
Group type: COMPARATOR
Intervention: Placebo taken at 20.00 hours for 1 week
Number of subjects: 15
Study 1319975 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg fluoxetine
Number of subjects: 30
Study 1319975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 3966424 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc supplements
Number of subjects: 28
Study 3966424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31071484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive bias modification, interpretation retraining (CBM‐I)
Number of subjects: 69
Study 31071484 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 69
Study 30016467 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate (0.5 mg/kg)
Number of subjects: 25
Study 30016467 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 27555998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Disk Arthroplasty (CDA)
Number of subjects: 0
Study 27555998 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior Cervical Diskectomy and Fusion (ACDF)
Number of subjects: 0
Study 27555998 — intervention group
Group type: COMPARATOR
Intervention: Control group (ACDF)
Number of subjects: 0
Study 24814857 — intervention group
Group type: EXPERIMENTAL
Intervention: DFPP combined with oral methylprednisolone
Number of subjects: 35
Study 24814857 — intervention group
Group type: COMPARATOR
Intervention: Oral methylprednisolone alone
Number of subjects: 35
Study 22210565 — intervention group
Group type: EXPERIMENTAL
Intervention: Group care
Number of subjects: 241
Study 22210565 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 241
Study 22210565 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HbA(1c)
Number of subjects: 241
Study 20083690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser (PDL) (595 nm)
Number of subjects: 15
Study 20083690 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium titanyl phosphate (KTP) laser (532 nm)
Number of subjects: 15
Study 20083690 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrodesiccation
Number of subjects: 15
Study 18036977 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week standard hospital rehabilitation program supplemented with an exercise-training program (n=11)
Number of subjects: 20
Study 18036977 — intervention group
Group type: COMPARATOR
Intervention: 12-week standard rehabilitation program at home (n=9)
Number of subjects: 20
Study 16651327 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (12 mg/kg per day, up to a maximum of 500 mg/day) for 5 days
Number of subjects: 49
Study 16651327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 13130174 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-45 min of physiotherapy twice daily
Number of subjects: 30
Study 13130174 — intervention group
Group type: COMPARATOR
Intervention: Maximally 15 min of physiotherapy per day for 5 days
Number of subjects: 30
Study 13130174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received dexamphetamine to achieve alertness
Number of subjects: 30
Study 13130174 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intensity of physiotherapy combined with dexamphetamine
Number of subjects: 30
Study 10998029 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 23
Study 10998029 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 23
Study 8868605 — intervention group
Group type: EXPERIMENTAL
Intervention: En-bloc-esophagectomy (EB)
Number of subjects: 26
Study 8868605 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhiatal blunt esophagectomy with dissection of all reachable lymph nodes (ESD)
Number of subjects: 26
Study 8868605 — intervention group
Group type: COMPARATOR
Intervention: Systematic dissection (SD)
Number of subjects: 26
Study 8868605 — intervention group
Group type: COMPARATOR
Intervention: Blunt dissection
Number of subjects: 26
Study 8868605 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (SD, ESD, EB)
Number of subjects: 26
Study 8868605 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative lymph node involvement
Number of subjects: 26
Study 8868605 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive lymph node involvement
Number of subjects: 26
Study 1519783 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine (8 micrograms.kg‐1 in 4 ml over 2 min)
Number of subjects: 18
Study 1519783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine (8 micrograms.kg‐1 in 10 ml over 14 min)
Number of subjects: 18
Study 1519783 — intervention group
Group type: COMPARATOR
Intervention: Epidural saline (4 ml over 2 min)
Number of subjects: 18
Study 1519783 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (10 ml over 14 min)
Number of subjects: 18
Study 6227643 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% erythromycin and 5% benzoyl peroxide combination gel
Number of subjects: 165
Study 6227643 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide gel
Number of subjects: 165
Study 6227643 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% erythromycin gel
Number of subjects: 165
Study 6227643 — intervention group
Group type: COMPARATOR
Intervention: gel vehicle
Number of subjects: 165
Study 30912475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 52
Study 30912475 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 28644740 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural activation
Number of subjects: 59
Study 28644740 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 59
Study 28644740 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 59
Study 26458917 — intervention group
Group type: EXPERIMENTAL
Intervention: MATCH‐ADTC
Number of subjects: 200
Study 26458917 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 23426342 — intervention group
Group type: EXPERIMENTAL
Intervention: VR simulation training
Number of subjects: 225
Study 20305057 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus A9 (BA9) at doses from 0.0075 mg/kg to 0.25 mg/kg
Number of subjects: 28
Study 20305057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 20305057 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus A9 (BA9)
Number of subjects: 28
Study 19930788 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 0.15% nasal spray (2 sprays/nostril twice daily)
Number of subjects: 526
Study 19930788 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 0.10% nasal spray (2 sprays/nostril twice daily)
Number of subjects: 526
Study 19930788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 526
Study 19930788 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 0.15% nasal spray
Number of subjects: 526
Study 19930788 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 0.15% and 0.10% nasal sprays
Number of subjects: 526
Study 19930788 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 0.15%
Number of subjects: 526
Study 19930788 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 0.10%
Number of subjects: 526
Study 17197583 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine leiomyoma embolization
Number of subjects: 66
Study 17197583 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic occlusion of uterine arteries
Number of subjects: 66
Study 15636168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cecropia obtusifolia
Number of subjects: 43
Study 15636168 — intervention group
Group type: EXPERIMENTAL
Intervention: Marrubium vulgare
Number of subjects: 43
Study 11716226 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant methotrexate and radiotherapy
Number of subjects: 0
Study 11716226 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in oropharyngeal cancer
Number of subjects: 0
Study 11716226 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (unspecified)
Number of subjects: 0
Study 11716226 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of methotrexate with radiotherapy
Number of subjects: 0
Study 9205339 — intervention group
Group type: EXPERIMENTAL
Intervention: Information given to patients in their own home before admission and again on their first day in hospital.
Number of subjects: 40
Study 9205339 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract).
Number of subjects: 40
Study 7957366 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial surfactant (Exosurf)
Number of subjects: 44
Study 2442536 — intervention group
Group type: EXPERIMENTAL
Intervention: Bornaprolol 40 mg
Number of subjects: 12
Study 2442536 — intervention group
Group type: EXPERIMENTAL
Intervention: Bornaprolol 80 mg
Number of subjects: 12
Study 2442536 — intervention group
Group type: EXPERIMENTAL
Intervention: Bornaprolol 120 mg
Number of subjects: 12
Study 2442536 — intervention group
Group type: EXPERIMENTAL
Intervention: Bornaprolol 240 mg
Number of subjects: 12
Study 2442536 — intervention group
Group type: EXPERIMENTAL
Intervention: Bornaprolol 480 mg
Number of subjects: 12
Study 2442536 — intervention group
Group type: EXPERIMENTAL
Intervention: Bornaprolol 960 mg
Number of subjects: 12
Study 2442536 — intervention group
Group type: EXPERIMENTAL
Intervention: Bornaprolol (various doses)
Number of subjects: 12
Study 2442536 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29807824 — intervention group
Group type: EXPERIMENTAL
Intervention: 1·1 GBq radioactive iodine after rhTSH
Number of subjects: 726
Study 29807824 — intervention group
Group type: EXPERIMENTAL
Intervention: 3·7 GBq radioactive iodine after rhTSH
Number of subjects: 726
Study 29807824 — intervention group
Group type: EXPERIMENTAL
Intervention: 1·1 GBq radioactive iodine after thyroid hormone withdrawal
Number of subjects: 726
Study 29807824 — intervention group
Group type: EXPERIMENTAL
Intervention: 3·7 GBq radioactive iodine after thyroid hormone withdrawal
Number of subjects: 726
Study 27869576 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages with visual and textual metaphors
Number of subjects: 256
Study 27869576 — intervention group
Group type: EXPERIMENTAL
Intervention: Messages with straightforward visuals and textual metaphors
Number of subjects: 256
Study 27869576 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based metaphor messages
Number of subjects: 256
Study 27869576 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 256
Study 25019111 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromelain
Number of subjects: 80
Study 25019111 — intervention group
Group type: COMPARATOR
Intervention: Analgesic (only if required)
Number of subjects: 80
Study 25019111 — intervention group
Group type: COMPARATOR
Intervention: Control (analgesic only)
Number of subjects: 80
Study 22246515 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV risk-reduction intervention
Number of subjects: 0
Study 22246515 — intervention group
Group type: COMPARATOR
Intervention: Health-promotion control
Number of subjects: 0
Study 19941694 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (n=19)
Number of subjects: 37
Study 19941694 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=18)
Number of subjects: 37
Study 18272475 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (80 mg/m²/day for four weeks, repeated every six weeks for a total of four courses)
Number of subjects: 360
Study 18272475 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m² on days 1, 8, and 15, repeated every four weeks for a total of six courses)
Number of subjects: 360
Study 18272475 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 360
Study 18272475 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 360
Study 16524650 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component analysis of kinetic lifting waveforms
Number of subjects: 0
Study 14631184 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic endoscopic evaluation of swallowing (FEES)
Number of subjects: 1
Study 14631184 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy
Number of subjects: 1
Study 10627101 — intervention group
Group type: EXPERIMENTAL
Intervention: CMCA intervention
Number of subjects: 15
Study 10627101 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study 9420113 — intervention group
Group type: EXPERIMENTAL
Intervention: CAGE screening test
Number of subjects: 1118
Study 9420113 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Michigan Alcoholism Screening Test
Number of subjects: 1118
Study 9420113 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Use Disorders Identification Test
Number of subjects: 1118
Study 9420113 — intervention group
Group type: COMPARATOR
Intervention: Structured Clinical Interview
Number of subjects: 1118
Study 1286495 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.7 mg, intravenously)
Number of subjects: 196
Study 1286495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 4023558 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel therapy
Number of subjects: 45
Study 31810023 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate delivery
Number of subjects: 704
Study 31810023 — intervention group
Group type: COMPARATOR
Intervention: Expectant monitoring
Number of subjects: 704